Arbutus Biopharma Corporation (ABUS) Fair Value 2026

ABUS · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.1 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (30/100)

Quick Summary — As of 2026-08-28, Arbutus Biopharma Corporation (ABUS) trades at $5.07, versus a $5.29 median fair value across its 2 active models — 4.3% above the current price. QOC: 7.1/10. Value Trap Risk: 30/100 (LOW). 2/13 models active.

Key Facts

Ticker
ABUS
Price
$5.07
Quality Score
7.1/10
Value Trap Risk
30/100
Models Active
2/13
Last Updated
Strength: ML-RIV suggests +104.4% upside with 46% confidence
Risk: Limited model coverage (2/13) may reduce confidence

Is Arbutus Biopharma Corporation (ABUS) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Arbutus Biopharma Corporation (ABUS) appears fairly valued as of : the median of 2 independent fair value estimates is $5.29, within 4.3% of the current price of $5.07. Estimates range from $0.22 to $10.36. ABUS scores 7.1/10 on fundamental quality and 30/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. ABUS’s +4.3% gap is narrower than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Arbutus Biopharma Corporation Stock in 2026? →

What Fair Value Does Each Model Give ABUS?

2 Intrinsic Value Models vs. Current Price ($5.07)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $10.36 +104.4%
Relative · Low Conviction
 $0.22 -95.7%

All Models Active

All 2 models are displayed above.

What Is Arbutus Biopharma Corporation (ABUS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Arbutus Biopharma Corporation presents a highly debated valuation profile at its current price of $5.07. The median intrinsic value is estimated at $5.29 (+4.3% median upside), masking a wide model spread between the 1 bullish models and 1 bearish models. Model dispersion is worth noting: ML-RIV targets $10.36 (+104.4%), versus Regime Cross at $0.22 (-95.7%). This +200.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About ABUS?

2 of 13 models are currently active for ABUS. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for ABUS is $5.29 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ABUS Rank in Biotechnology?

Among 625 Biotechnology stocks, ABUS ranks #43 by Quality of Company score. CirclFi's QOC score of 7.1/10 evaluates 32 fundamental signals. A score of 7.1 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Arbutus Biopharma Corporation operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating ABUS should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ABUS a Value Trap?

CirclFi's Value Trap algorithm assigns ABUS a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Arbutus Biopharma Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Arbutus Biopharma Corporation's fundamental quality profile registers 7.1/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +200.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ABUS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ABUS's 2 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Arbutus Biopharma Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

SRPTSarepta Therapeutics, Inc.QOC 7.1URGNUroGen Pharma Ltd.QOC 7.1ARCTArcturus Therapeutics Holdings Inc.QOC 7.2MRNAModerna, Inc.QOC 7.0ARVNArvinas, Inc.QOC 7.2SEERSeer, Inc.QOC 7.0CYCNCyclerion Therapeutics, Inc.QOC 5.6NGNENeurogene Inc.QOC 4.9GALTGalectin Therapeutics Inc.QOC 4.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: SRPT · URGN · ARCT · MRNA · ARVN · SEER · CYCN · NGNE · GALT · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ABUS?

6 companies across all industries closest to ABUS’s Quality of Company score of 7.1/10.

GGBGerdau S.A.QOC 7.1SANBanco Santander, S.A.QOC 7.1CRWSCrown Crafts, Inc.QOC 7.1SDGRSchrödinger, Inc.QOC 7.1IOTSamsara Inc.QOC 7.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GGB · SAN · CRWS · SDGR · IOT · NVDA

Where Does ABUS Sit in CirclFi's Biotechnology Rankings?

ABUS is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Arbutus Biopharma Corporation’s Valuation?

What is Arbutus Biopharma Corporation's intrinsic value in 2026?

CirclFi puts Arbutus Biopharma Corporation (ABUS)'s intrinsic value at $5.29 — the median of 2 independent model estimates as of 2026-08-28, ranging from $0.22 to $10.36. The Quality of Company score is 7.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ABUS overvalued or undervalued right now?

At $5.07, 1 of 2 active models suggest ABUS may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $5.29, within 4.3% of the current price of $5.07 — a consensus view that ABUS is fairly valued. The assessment depends on which methodology best fits Arbutus Biopharma Corporation's business model in Biotechnology.

What does a Quality of Company score of 7.1 mean for ABUS?

Arbutus Biopharma Corporation's QOC of 7.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on ABUS?

CirclFi analyzes ABUS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is ABUS a value trap in 2026?

Arbutus Biopharma Corporation's Value Trap score is 30/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Arbutus Biopharma Corporation (ABUS) has a median fair value of $5.29 — within 4.3% of the current price of $5.07 — as of 2026-08-28.” Source: circlfi.com/stock/ABUS/ · Methodology
Primary sources for this ABUS valuation
  • Financial statements: Arbutus Biopharma Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001447028) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ABUS as of ; valuations recomputed .